ASND
Ascendis Pharma A/S
$210.49
+$0.94(+0.45%)
63
Overall
--
Value
63
Tech
--
Quality
Market Cap
$13.18B
Volume
600.98K
52W Range
$118.03 - $223.19
Target Price
$254.19
Company Overview
| Mkt Cap | $13.18B | Price | $210.49 |
| Volume | 600.98K | Change | +0.45% |
| P/E Ratio | -34.9 | Open | $209.20 |
| Revenue | $363.6M | Prev Close | $209.55 |
| Net Income | $-378.1M | 52W Range | $118.03 - $223.19 |
| Div Yield | N/A | Target | $254.19 |
| Overall | 63 | Value | -- |
| Quality | -- | Technical | 63 |
No chart data available
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest News
FDA Calendar: These Are the Upcoming FDA Drug Approvals
Solomon Oladipupo•3 days ago
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo
TipRanks Auto-Generated Intelligence Newsdesk•7 days ago
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Alkermes (ALKS)
Catie Powers•10 days ago
Morgan Stanley Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
TipRanks Auto-Generated Intelligence Newsdesk•10 days ago
Ascendis Pharma Achieves Strong Q3 2025 Financial Results Amid Product Expansion
TipRanks Auto-Generated Newsdesk•11 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ASND | $210.49 | +0.4% | 600.98K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |